logo
Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer

Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer

Yahoo5 days ago
LUND, SE / ACCESS Newswire / July 16, 2025 / Cantargia (STO:CANTA)
Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54%
Strong efficacy signal observed in non-squamous NSCLC patients previously treated with the PD-1 inhibitor pembrolizumab, with median OS of 26.7 months and 91% ORR, including two complete responses
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of results from the CANFOUR trial with nadunolimab in combination with chemotherapy in the peer reviewed journal Lung Cancer. 40 patients with advanced NSCLC were treated with nadunolimab in combination with cisplatin/gemcitabine or carboplatin/pemetrexed for 4-6 cycles before continuing with nadunolimab as monotherapy or together with only gemcitabine or pemetrexed. The trial showed a manageable safety profile and encouraging median survival times, especially in patients with prior treatment with checkpoint inhibitors.
"These positive data published in Lung Cancer describe an important potential opportunity for nadunolimab, with possibilities to address a major unmet medical need" said Damian Marron, interim CEO of Cantargia. "We are particularly encouraged by the strong signal in the non-squamous NSCLC patients post PD-1 inhibitor treatment".
Lung cancer is one of the most common malignances worldwide and a leading cause of cancer-related deaths, with 84% of cases of the non-small cell lung cancer (NSCLC) type [1]. Immune checkpoint inhibitors targeting programmed death (ligand) 1 (PD-1/PD-L1) form part of the standard of care alongside chemotherapy for patients with advanced/metastatic NSCLC [2]. Treatment of NSCLC with immune checkpoint inhibitors can markedly improve tumor response rates and prolong survival, but not all patients respond to treatment and the development of treatment resistance is frequent [3, 4].
The CANFOUR Phase 2a trial with 40 advanced/metastatic NSCLC patients investigated nadunolimab in combination with cisplatin/gemcitabine (NCG) or carboplatin/pemetrexed (NCP) in first-line (1L), or in second-line (2L) after relapsing on pembrolizumab. Nadunolimab at doses of 1, 2.5 or 5 mg/kg were combined with chemotherapy for 4-6 cycles, followed by nadunolimab monotherapy or together with only gemcitabine or pemetrexed. Promising efficacy was reported with an OS of 13.7 months, which is observed to be better than historical references from randomized clinical trials of cisplatin/gemcitabine or platinum/pemetrexed in advanced NSCLC (median OS 10.3 and 11.3 months) [5,6].
Interestingly, highest efficacy was seen in patients previously treated with pembrolizumab (n=17) as compared to treatment naïve patients (n=23) (ORR 71% vs 44%; OS 15.7 vs 11.5 months). The 2L post-pembrolizumab patients had a markedly different tumor microenvironment at baseline with higher number of IL1RAP-positive immune cells, CD163+ macrophages, CD56+ NK cells and CD8+ T cells. Best response was seen in 2L non-squamous patients (n=11) which showed an outstanding ORR of 91%, PFS of 10.4 months and OS of 26.7 months, including two complete responders.
20 patients continued with nadunolimab monotherapy after having discontinued chemotherapy. One patient attained a complete response during monotherapy treatment, indicating a continued clinical effect of nadunolimab after completion of chemotherapy.
The combination showed a manageable safety profile with neutropenia being the most frequent reported adverse event.
The results support further investigation of the potential benefit in patients with non-squamous histology who previously progressed on immune checkpoint inhibitors, and to assess the potential benefit of continued nadunolimab monotherapy.
The publication, titled "Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet", by Paulus et al, is available online at the Lung Cancer | Journal | ScienceDirect.com by Elsevier and will be published Cantargia's web page.
References[1] Kratze et al. Cancer 2024 130(8) 1330-1348[2] Owen et al JCO Oncol Pract 2024 20(7) 893-898[3] Bagshi et al Ann Rev Path 2021 16 223-249[4] Jenkins et al Br J Cancer 2018 118(1) 9-16[5] Scagliotti et al J Clin Onc 2008 26(21) 3543-3551[6] Gandhi et al N Engl J Med 2018 378(22) 2078-2092
For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: damian.marron@cantargia.com
About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.
About nadunolimab (CAN04)The antibody nadunolimab binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. Nadunolimab can thereby counteract the IL-1 system which contributes to the immune suppressive tumor microenvironment and the development of resistance to chemotherapy. Nadunolimab is investigated in multiple clinical trials; the phase I/IIa trial CANFOUR, NCT03267316, evaluates nadunolimab in combination with standard chemotherapies in patients with pancreatic ductal adenocarcinoma (PDAC) (gemcitabine/nab-paclitaxel) or non-small cell lung cancer (NSCLC) (platinum-based chemotherapies). Positive data show durable responses for combination therapy in 73 PDAC patients, resulting in a median iPFS of 7.2 months and median OS of 13.2 months. An even higher median OS of 14.2 months was observed in a subgroup of patients with high tumor levels of IL1RAP. Strong efficacy was also observed in 40 NSCLC patients with median PFS of 7.2 months and a response rate of 55%; even higher responses were observed in non-squamous NSCLC patients. Early efficacy data from the phase 1b/2 trial TRIFOUR, NCT05181462, also shows signs of promising efficacy in TNBC with a 60% response rate for nadunolimab combined with carboplatin/gemcitabine.
AttachmentsCantargia announces publication of clinical data showing benefit of nadunolimab combination therapy in advanced lung cancer
SOURCE: Cantargia
View the original press release on ACCESS Newswire
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EU chief von der Leyen heads to Scotland for trade talks with Trump
EU chief von der Leyen heads to Scotland for trade talks with Trump

Yahoo

time12 minutes ago

  • Yahoo

EU chief von der Leyen heads to Scotland for trade talks with Trump

By Andrew Gray and Andrea Shalal BRUSSELS/EDINBURGH (Reuters) -EU Commission President Ursula von der Leyen headed to Scotland on Saturday ahead of a meeting with U.S. President Donald Trump on Sunday afternoon, commission spokespeople said, as EU officials said the two sides were nearing a trade agreement. Trump, in Scotland for a few days of golfing and bilateral meetings, told reporters upon his arrival on Friday evening that he was looking forward to meeting with von der Leyen, calling her a "highly respected" leader. He repeated his view that there was a 50-50 chance that the U.S. and the 27-member European Union could reach a framework trade pact, adding that Brussels wanted to "make a deal very badly". If it happened, he said it would be the biggest trade agreement reached yet by his administration, surpassing the $550 billion accord agreed with Japan earlier this week. The White House has released no details about the planned meeting or the terms of the emerging agreement. The European Commission on Thursday said a negotiated trade solution with the United States was within reach, even as EU members voted to approve counter-tariffs on 93 billion euros ($109 billion) of U.S. goods in case the talks collapse. To get a deal, Trump said the EU would have to "buy down" that tariff rate, although he gave no specifics. EU diplomats say a possible deal between Washington and Brussels would likely include a broad 15% tariff on EU goods imported into the U.S., mirroring the U.S.-Japan deal, along with a 50% tariff on European steel and aluminum. The broad tariff rate would be half the 30% duties that Trump has threatened to slap on EU goods from August 1. It remains unclear if Washington will agree to exempt the EU from sectoral tariffs on automobiles, pharmaceuticals and other goods that have already been announced or are pending. Combining goods, services and investment, the EU and the United States are each other's largest trading partners by far. The American Chamber of Commerce in Brussels warned in March that any conflict jeopardized $9.5 trillion of business in the world's most important commercial relationship. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Eddie Howe Clarifies Isak's Situation Ahead of Arsenal Clash
Eddie Howe Clarifies Isak's Situation Ahead of Arsenal Clash

Yahoo

time42 minutes ago

  • Yahoo

Eddie Howe Clarifies Isak's Situation Ahead of Arsenal Clash

Eddie Howe confirms no contract talks with Swedish striker amid Liverpool links Eddie Howe Clarifies Isak's Situation Ahead of Arsenal Clash Newcastle United manager Eddie Howe's responded to swirling rumors surrounding the future of Alexander Isak denying any current negotiations over contract renewal with the Swedish forward. No Contract Talks Yet Speaking ahead of Newcastle's pre season friendly against Arsenal, Howe stated: "To my knowledge, there're no ongoing negotiations over Isak's contract. That could happen later" Despite Isak still having three years left on his deal speculation surged this week after the 25 year old missed the club's Asia tour due to reported thigh injury. Behind the Scenes Talks? Multiple outlets including The Athletic & Daily Mail, claim Isak's informed the club he wants clarity on possible move with Liverpool reportedly keen on his signature. However, Howe remained firm but diplomatic: "Isak's been amazing for the team. He's loved in the dressing room. We'd like him to continue his journey with us" He admitted Isak's under pressure: "He knows he'll be in the headlines daily. That's not easy for anyone in this position" €170M Price Tag Set Reports suggest Newcastle've placed 170 million Euro price tag on Isak an amount widely seen as deal breaker for potential buyers.

Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment
Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment

Yahoo

time42 minutes ago

  • Yahoo

Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment

Eli Lilly recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a crucial therapeutic area. During the same period, LLY registered a 5% share price increase, notably outpacing the broader market's 1% rise over the past week. This uptrend in LLY's stock could be attributed to investors' optimism about donanemab's potential impact. Additionally, the company's collaboration with Gate Bioscience to develop novel therapies further strengthens its innovative capabilities, adding weight to its share price momentum amid broader market gains. We've spotted 2 risks for Eli Lilly you should be aware of, and 1 of them doesn't sit too well with us. Find companies with promising cash flow potential yet trading below their fair value. The recent positive opinion from the CHMP about Eli Lilly's Alzheimer's drug, donanemab, could significantly enhance the company's revenue and earnings forecasts. This development positions the company well for future growth, adding credibility to its strategic focus on expanding into high-demand therapeutic areas like oncology and immunology. Coupled with its collaboration with Gate Bioscience, these advances may provide substantial long-term benefits to the company's bottom line. Over the past five years, Eli Lilly's total return, which includes both share price growth and dividends, was a very large 473.44%. This long-term growth far outpaces the recent 1% rise in the broader market over the past year, bolstering investor confidence in the company's strategic trajectory and robust pipeline. In comparison to the US Pharmaceuticals industry, which saw a decline of 5.9% over the past year, Eli Lilly's sharp uptick in share price highlights its strong performance relative to industry peers. The company's earnings growth was a robust 80.9% over the past year, indicative of its potent execution in a challenging market. The current share price of US$812.69, when set against the analyst consensus price target of US$952.27, suggests there is room for potential growth. However, it also indicates investor caution, likely weighed down by concerns over competitive pressure and pricing dynamics. Investors might find reassurance in the company's ongoing manufacturing and R&D investments, which aim to mitigate risks and sustain growth in the coming years. Understand Eli Lilly's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store